Back to Results

A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis

Primary Objective

To determine the RP2D and schedule of TL-895 in each cohort. The SRC will determine the RP2D and schedule for Cohorts 1, 2 and 3 based on safety and tolerability data obtained from each arm of that cohort.

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Brandon Mcmahon,  MD

Brandon Mcmahon, MD

Study ID

Protocol Number: 20-3032

More information available at ClinicalTrials.gov: NCT04655118

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers